← Feed

u/oquido

2 theses · first seen Sep 4, 2026
WindowThesesResolvedWinsWin rateAvg returnMedian return
1d——————
3d——————
1w——————
1m——————
3m——————
6m——————
1y——————

Past performance does not predict future results. Informational only, not investment advice.

Thesis history

$ALGSr/pennystocksStock Infobullish
u/oquido · 405d ago1 prior · awaiting results
Long ALGS

$ALGS, over 5000% potential with Best-in-class HBV & MASH candidates with strong data. The most complete independent report available for this company - Long read

Aligos Therapeutics has best-in-class HBV and MASH candidates with superior clinical data compared to current standards of care. With strong management (CEO formerly built companies acquired for billions), $122.9M cash runway, and leading pipeline assets (ALG-000184 as a capsid assembly modulator and a leading MASH candidate), the company has potential for significant appreciation from current $9.53 stock price.

At post $10.25live price unavailable
1d+4.9%
3d-4.5%
1w-4.4%
1m-7.4%
3m+4.9%
6m-33.6%
1y-45.8%
original post →
$CGTXr/pennystocksStock Infobullish
u/oquido · 423d ago1 prior · awaiting results
“I hold a long position”

$CGTX, Upcoming Plans - Comprehensive Discussion with the IR Representative

Cognition Therapeutics is positioned for strong Phase 3 progression with successful FDA alignment for a dual six-month Alzheimer's trial design and promising DLB data showing high potential for zervimesine (CT1812). Recent capital raises and delisting risk resolution enable active partnership discussions with Tier 1 pharmas in the near term.

At post $2.61Now $0.71-72.8% since postedas of Nov 2, 4:15 PM ET
1d—
3d-8.0%
1w-16.9%
1m-40.6%
3m-32.6%
6m-59.4%
1y-60.5%
original post →

End of results.